Clinical Trial Update: Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenalidomide with rituximab in refractory or relapsed primary central nervous system lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Institut Curie | Conditions: Lymphoma, Relapse | Phase 2 | Status: COMPLETED